Skip to main content

Table 1 Subject characteristics

From: Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

Total study subjects   17  
Age, median (Range), years   63 48–81
Sex Male 14 82 %
  Female 3 18 %
ECOG PS pretreatment 0 8 47 %
  1 9 53 %
Melanoma Sub-Type Cutaneous 15 88 %
  Mucosal 2 3 %
Prior lines of therapy, n (%) 0 3 18 %
  1 4 24 %
  2 4 24 %
  ≥3 6 35 %
Median prior lines of therapy (% pretreated)   2 83 %
Prior Interleukin-2   5 29 %
Prior Ipilimumab   4 24 %
Number of metastatic sites 1 6 35 %
  2 4 24 %
  ≥3 7 41 %
  M1a 1 6 %
  M1b 5 29 %
  M1c 11 65 %